Final week for award nominations
03 September, 2002 by Iain ScottThere's barely a week left for you to enter the inaugural Australian Biotechnology News awards, but the good news is that you still have time.
Singapore feature: money or nothing: Australia versus Singapore Inc.
02 September, 2002 by David BinningThe comparison of the Australian and Singaporean biotech sectors highlights a fundamental principle of this highly volatile business: biotech needs lots of cash, but money burns pretty fast without good brains to spend it.
Researchers back beleaguered Trounson
29 August, 2002 by Melissa TrudingerLeading scientists came out today in support of beleaguered Stem Cell Centre of Excellence CEO Prof Alan Trounson, and urged the Federal government to pass the Stem Cell Bill, which is expected to go to a vote in the House of Representatives later today.
ASX to help lift biotech's public image
28 August, 2002 by Melissa TrudingerThe Australian Stock Exchange is poised to take an active role in the development of a healthy public biotech sector in Australia.
Investment feature: patently obvious
27 August, 2002 by David BinningTo most, patents are the life blood of innovation and discovery for the biotech sector, while to others they are a scourge. But as lawyers and industry experts warn, careless handling of the finer points of intellectual property can be catastrophic to both commercial and academic organisations.
Investment feature: public image Ltd
27 August, 2002 by Tanya HollisMuch is made of Australia's scientific intellectual capital and the opportunities that it offers. But according to one of the world's largest accounting groups, it is a dangerous myth that states successful companies will automatically flow from the nation's renowned research achievements.
Location, location, location: where should you build your biobusiness?
26 August, 2002 by David BinningThe most important concept for Australian biotechnology companies to grasp when building a nest, according to industry and property development experts, is proximity.
US VC warns of early IPO dangers
23 August, 2002 by Melissa TrudingerDon't go public too early, use incubators to get your company off the ground and maximise collaborative opportunities, were the key messages from US venture capitalist Peter Morgan Kash at the AusBiotech 2002 conference this week.
Second BIF grant gives Protagonist an edge
22 August, 2002 by Pete YoungFor drug design start-up Protagonist, tucking a second BIF grant in as many years under its belt should help smooth future discussions with commercial partners.
Heavy R&D spend sees Antisense book $6.3m loss
22 August, 2002 by David BinningBiopharmaceutical research and development company Antisense Therapeutics reported on Wednesday a net loss of $6.3 million for the 12 months to June 30, 2002, driven largely by heavy early-stage expenditure on R&D, the company said.
IDT posts profit record number eight
22 August, 2002 by David BinningAustralian drug discovery company International Drug Technologies has announced a record 14 per cent jump in full year net profit to $4.2 million.
Put your pedal to the metal: BIO chief
20 August, 2002 by Melissa TrudingerIt's time for biobusiness to accelerate without looking back, the chair of the US Biotechnology Industry Organisation (BIO), David Robinson, told the AusBiotech conference in Melbourne this week.
Chemeq tops Deloitte WA index
19 August, 2002 by Iain ScottWestern Australian biotech Chemeq has topped a Deloitte Touche Tohmatsu index highlighting the market performance of WA listed companies over the last two years.
Peacock to head Fed research advisory panel
16 August, 2002 by Iain ScottCSIRO Plant Industry chief Dr Jim Peacock has been selected to head the Federal government's advisory panel on national research priorities.
Careers in chemistry
16 August, 2002 by Claire DobleA presentation on Careers for Chemists in Biotechnology, scheduled for Monash University next fortnight, has proved popular.
